(1888PressRelease)
April 27, 2009 - Results from an ongoing Phase IIa study showed that MK-7009, an investigational oral hepatitis C virus (HCV) protease inhibitor under development by Merck & Co., Inc., Whitehouse Station, N.J., U.S.A., in combination therapy significantly improved rapid viral response, defined as viral suppression to undetectable levels within 28 days, compared to placebo in combination therapy in previously untreated (treatment-naïve) patients infected with chronic HCV genotype 1, one of the most difficult to treat genotypes of HCV¹ (p
###
